What is HC Wainwright’s Forecast for Pharvaris Q3 Earnings?

Pharvaris N.V. (NASDAQ:PHVS) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Pharvaris in a research note issued to investors on Friday, August 14th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.92) per share for the quarter, down from their previous estimate of ($0.76). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.08) per share. HC Wainwright also issued estimates for Pharvaris’ Q4 2026 earnings at ($0.98) EPS, FY2026 earnings at ($3.41) EPS, Q1 2027 earnings at ($0.99) EPS, Q2 2027 earnings at ($0.89) EPS, Q3 2027 earnings at ($0.77) EPS, FY2027 earnings at ($3.30) EPS, FY2028 earnings at ($0.56) EPS and FY2029 earnings at $3.09 EPS.

Several other analysts also recently commented on the stock. Morgan Stanley lifted their target price on shares of Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a report on Thursday, June 25th. New Street Research set a $60.00 price target on Pharvaris in a research note on Friday. Wells Fargo & Company began coverage on Pharvaris in a report on Wednesday, July 15th. They set an “overweight” rating and a $55.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. Finally, Guggenheim lifted their price objective on shares of Pharvaris from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $51.08.

Pharvaris Trading Up 0.5%

NASDAQ PHVS opened at $35.32 on Tuesday. The stock has a 50 day moving average of $33.79 and a 200-day moving average of $30.17. Pharvaris has a 12 month low of $20.65 and a 12 month high of $36.93. The company has a market cap of $2.31 billion, a PE ratio of -11.58 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06).

Institutional Trading of Pharvaris

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in shares of Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Legal & General Group Plc grew its stake in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the period. Amundi grew its stake in Pharvaris by 2,741,600.0% during the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after purchasing an additional 27,416 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after purchasing an additional 7,879 shares in the last quarter.

Insider Activity at Pharvaris

In related news, Director Viviane Monges sold 9,667 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $30.29, for a total value of $292,813.43. Following the completion of the sale, the director directly owned 5,500 shares in the company, valued at $166,595. This represents a 63.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO David W. Nassif sold 10,000 shares of the stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $30.31, for a total value of $303,100.00. Following the completion of the sale, the chief financial officer directly owned 120,300 shares of the company’s stock, valued at approximately $3,646,293. The trade was a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 156,030 shares of company stock valued at $5,304,914 in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.